1 results match your criteria: "and Sydney Vital Translational Cancer Research Centre[Affiliation]"
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
Theranostics
January 2018
Departments of Nuclear Medicine, Medical Oncology and Surgery, Royal North Shore Hospital, Sydney Medical School and Faculty of Health Sciences, University of Sydney, and Sydney Vital Translational Cancer Research Centre, Sydney, Australia.
PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different grades of disease. The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter.
View Article and Find Full Text PDF